Claudia Goettsch1, Hiroshi Iwata1, Joshua D Hutcheson1, Christopher J O'Donnell1, Roland Chapurlat1, Nancy R Cook1, Masanori Aikawa1, Pawel Szulc1, Elena Aikawa2. 1. From the Center for Interdisciplinary Cardiovascular Sciences (C.G., H.I., J.D.H., M.A., E.A.) and Center for Excellence in Vascular Biology (M.A., E.A.), Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Boston VA Healthcare, Department of Cardiology, MA (C.J.O.); INSERM UMR 1033, University of Lyon, Hôpital Edouard Herriot, Department of Rheumatology and Bone Pathology, France (R.C., P.S.); and Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.R.C.). 2. From the Center for Interdisciplinary Cardiovascular Sciences (C.G., H.I., J.D.H., M.A., E.A.) and Center for Excellence in Vascular Biology (M.A., E.A.), Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Boston VA Healthcare, Department of Cardiology, MA (C.J.O.); INSERM UMR 1033, University of Lyon, Hôpital Edouard Herriot, Department of Rheumatology and Bone Pathology, France (R.C., P.S.); and Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.R.C.). eaikawa@partners.org.
Abstract
OBJECTIVE: Genome-wide association studies and preclinical studies demonstrated a role of sortilin in lipid metabolism, inflammation, and vascular calcification-all cardiovascular risk factors. We evaluated the association of serum sortilin levels with the risk of major adverse cerebrovascular and cardiovascular events (MACCE) and the severity of abdominal aortic calcification (AAC). APPROACH AND RESULTS: A cohort of community-dwelling men aged ≥50 years (n=830) was assessed. At baseline, sortilin levels were measured by ELISA, and AAC was assessed on lateral spine scans obtained by dual-energy X-ray absorptiometry. Men aged ≥60 years (n=745) were followed up prospectively for the incidence of MACCE. During the median follow-up of 7.9 years, 76 MACCE occurred. The unadjusted incidence of MACCE across increasing sortilin quartiles was 8.0, 7.4, 19.8, and 20.3 per 1000 person-years. In multivariate-adjusted analysis, sortilin associated with increased risk of MACCE (hazard ratio, 1.70 per SD; 95% confidence interval, 1.30-2.20; P<0.001). The third and fourth quartiles associated with 3.42-fold (95% confidence interval, 1.61-7.25; P<0.005) and 3.82-fold (95% confidence interval, 1.77-8.26; P<0.001) higher risk of MACCE compared with the first quartile. High sortilin also predicted MACCE independent of traditional Framingham risk factors. Higher sortilin associated with higher odds of severe AAC (score>5) after adjustment for confounders (odds ratio, 1.43 per SD; 95% confidence interval, 1.10-1.85; P<0.01). The highest sortilin quartile associated with 2-fold higher odds of severe AAC (versus 3 lower quartiles combined). After adjustment for low-density lipoprotein cholesterol, the odds of severe AAC remained significant. CONCLUSIONS: In older men, higher serum sortilin levels associated with higher MACCE risk and severe AAC independently of relevant confounders, including C-reactive protein and low-density lipoprotein cholesterol. This finding, however, needs to be validated in other cohorts.
OBJECTIVE: Genome-wide association studies and preclinical studies demonstrated a role of sortilin in lipid metabolism, inflammation, and vascular calcification-all cardiovascular risk factors. We evaluated the association of serum sortilin levels with the risk of major adverse cerebrovascular and cardiovascular events (MACCE) and the severity of abdominal aortic calcification (AAC). APPROACH AND RESULTS: A cohort of community-dwelling men aged ≥50 years (n=830) was assessed. At baseline, sortilin levels were measured by ELISA, and AAC was assessed on lateral spine scans obtained by dual-energy X-ray absorptiometry. Men aged ≥60 years (n=745) were followed up prospectively for the incidence of MACCE. During the median follow-up of 7.9 years, 76 MACCE occurred. The unadjusted incidence of MACCE across increasing sortilin quartiles was 8.0, 7.4, 19.8, and 20.3 per 1000 person-years. In multivariate-adjusted analysis, sortilin associated with increased risk of MACCE (hazard ratio, 1.70 per SD; 95% confidence interval, 1.30-2.20; P<0.001). The third and fourth quartiles associated with 3.42-fold (95% confidence interval, 1.61-7.25; P<0.005) and 3.82-fold (95% confidence interval, 1.77-8.26; P<0.001) higher risk of MACCE compared with the first quartile. High sortilin also predicted MACCE independent of traditional Framingham risk factors. Higher sortilin associated with higher odds of severe AAC (score>5) after adjustment for confounders (odds ratio, 1.43 per SD; 95% confidence interval, 1.10-1.85; P<0.01). The highest sortilin quartile associated with 2-fold higher odds of severe AAC (versus 3 lower quartiles combined). After adjustment for low-density lipoprotein cholesterol, the odds of severe AAC remained significant. CONCLUSIONS: In older men, higher serum sortilin levels associated with higher MACCE risk and severe AAC independently of relevant confounders, including C-reactive protein and low-density lipoprotein cholesterol. This finding, however, needs to be validated in other cohorts.
Authors: Martin B Mortensen; Mads Kjolby; Stine Gunnersen; Jakob V Larsen; Johan Palmfeldt; Erling Falk; Anders Nykjaer; Jacob F Bentzon Journal: J Clin Invest Date: 2014-11-17 Impact factor: 14.808
Authors: Mads Kjolby; Olav M Andersen; Tilman Breiderhoff; Anja W Fjorback; Karen Marie Pedersen; Peder Madsen; Pernille Jansen; Joerg Heeren; Thomas E Willnow; Anders Nykjaer Journal: Cell Metab Date: 2010-09-08 Impact factor: 27.287
Authors: Axel Muendlein; Simone Geller-Rhomberg; Christoph H Saely; Thomas Winder; Gudrun Sonderegger; Philipp Rein; Stefan Beer; Alexander Vonbank; Heinz Drexel Journal: Atherosclerosis Date: 2009-03-19 Impact factor: 5.162
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: J Mazella; N Zsürger; V Navarro; J Chabry; M Kaghad; D Caput; P Ferrara; N Vita; D Gully; J P Maffrand; J P Vincent Journal: J Biol Chem Date: 1998-10-09 Impact factor: 5.157
Authors: Udo Hoffmann; Joseph M Massaro; Ralph B D'Agostino; Sekar Kathiresan; Caroline S Fox; Christopher J O'Donnell Journal: J Am Heart Assoc Date: 2016-02-22 Impact factor: 5.501
Authors: Agnese Irkle; Alex T Vesey; David Y Lewis; Jeremy N Skepper; Joseph L E Bird; Marc R Dweck; Francis R Joshi; Ferdia A Gallagher; Elizabeth A Warburton; Martin R Bennett; Kevin M Brindle; David E Newby; James H Rudd; Anthony P Davenport Journal: Nat Commun Date: 2015-07-07 Impact factor: 14.919
Authors: H N Buttenschøn; D Demontis; M Kaas; B Elfving; S Mølgaard; C Gustafsen; L Kaerlev; C M Petersen; A D Børglum; O Mors; S Glerup Journal: Transl Psychiatry Date: 2015-11-10 Impact factor: 6.222
Authors: Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky Journal: J Am Coll Cardiol Date: 2020-06-02 Impact factor: 24.094
Authors: Joshua D Hutcheson; Craig J Goergen; Frederick J Schoen; Masanori Aikawa; Peter Zilla; Elena Aikawa; Glenn R Gaudette Journal: Front Cardiovasc Med Date: 2019-02-14
Authors: Sumihiko Hagita; Maximillian A Rogers; Tan Pham; Jennifer R Wen; Andrew K Mlynarchik; Masanori Aikawa; Elena Aikawa Journal: Sci Rep Date: 2018-06-13 Impact factor: 4.379